Acumen Pharmaceuticals reported $78.6 million in cash as of September 2026, with resources expected to support operations into early 2027 and Phase 2 Alzheimer's trial results due in November. Additionally, Acuity Inc. reached a $675 million deal to acquire Parameter Technologies, aiming to expand its data center leak detection capabilities. The acquisition is expected to close in fiscal Q2 2027 and be accretive to Acuity's adjusted earnings per share.
The company expects to complete its acquisition of Parametrix in the second quarter of fiscal 2027, with the deal expected to contribute to adjusted diluted earnings per share in the same year.
Read the full storyThe company confirmed its cash runway extends into early 2027 as it prepares to release topline Phase 2 data for its Alzheimer's treatment, sabirnetug, in November.